Search

Displaying results 3681 - 3690 of 5263 in total
  1. Drug

    Dinutuximab

    go.drugbank.com/drugs/DB09077
    ApprovedInvestigational

    By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the

  2. Drug

    Biapenem

    go.drugbank.com/drugs/DB13028
    Investigational

    It is a carbapenem antibiotic with a methyl group on the 1-beta position, which gives it stability against degradation by dehydropeptidase I.[A275008]

  3. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  4. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase. … Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD.

  5. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.

  6. Drug

    Ximelagatran

    go.drugbank.com/drugs/DB04898
    ApprovedWithdrawn

    Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former.

    Synonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetate
  7. Drug

    Rilapladib

    go.drugbank.com/drugs/DB05119
    Investigational

    Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development.

  8. Drug

    Maxy-G34

    go.drugbank.com/drugs/DB05718
    Investigational

    Specifically, the amino acid sequence of MAXY-G34 differs from that of human wild type G-CSF at residues 16, 34, 40, 105 and 159. … It is being developed by Maxygen, Inc. for the treatment of chemotherapy-induced neutropenia.

  9. Drug

    Oxfendazole

    go.drugbank.com/drugs/DB11446
    InvestigationalVet approved

    This benzimidazole antihelminthic protects livestock from roundworm. strongyles, and pinworn.

  10. Drug

    Selicrelumab

    go.drugbank.com/drugs/DB14958
    Investigational

    Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).